• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

    11/14/24 5:49:14 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care
    Get the next $LYRA alert in real time by email
    SC 13G/A 1 tm2428137d11_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)*

      

    Lyra Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    55234L105

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 55234L105 Page 2 of 17

     

       
    1.

    Name of reporting persons

     

    Venrock Healthcare Capital Partners II, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 316,557 shares issuable upon the exercise of immediately exercisable warrants (“Warrants”) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 55234L105 Page 3 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Co-Investment Holdings II, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 55234L105 Page 4 of 17

     

       
    1.

    Name of reporting persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    PN

      

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 55234L105 Page 5 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
    2Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 55234L105 Page 6 of 17

     

       
    1.

    Name of reporting persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 55234L105 Page 7 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Management II, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 55234L105 Page 8 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

       

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

     

    CUSIP No. 55234L105 Page 9 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 55234L105 Page 10 of 17

     

       
    1.

    Name of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

     

    CUSIP No. 55234L105 Page 11 of 17

     

       
    1.

    Name of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,204,0942

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,204,0942

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,204,0942

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.8%3

    12.

    Type of Reporting Person (See Instructions)

     

    IN

        

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

    3This percentage is calculated based upon the sum of (i) 65,456,735 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024, and (ii) 1,204,094 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 55234L105 Page 12 of 17

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II LP”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment II”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP II LP, VHCP Co-Investment II, VHCP III LP, VHCP Co-Investment III, VHCP EG, VHCP Management II and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Lyra Therapeutics, Inc.

     

    Item 1.

     

      (a) Name of Issuer

     

    Lyra Therapeutics, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    480 Arsenal Way

    Watertown, MA 02472

     

    Item 2.

     

      (a) Name of Person Filing

     

    Venrock Healthcare Capital Partners II, L.P.

    VHCP Co-Investment Holdings II, LLC

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management II, LLC

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c) Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

     

     

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.001 per share

     

      (e) CUSIP Number

     

    55234L105

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned as of September 30, 2024:

     

    Venrock Healthcare Capital Partners II, L.P.   1,204,094(1)
    VHCP Co-Investment Holdings II, LLC   1,204,094(1)
    Venrock Healthcare Capital Partners III, L.P.   1,204,094(1)
    VHCP Co-Investment Holdings III, LLC   1,204,094(1)
    Venrock Healthcare Capital Partners EG, L.P.   1,204,094(1)
    VHCP Management II, LLC   1,204,094(1)
    VHCP Management III, LLC   1,204,094(1)
    VHCP Management EG, LLC   1,204,094(1)
    Nimish Shah   1,204,094(1)
    Bong Koh   1,204,094(1)

     

      (b) Percent of Class as of September 30, 2024:

     

    Venrock Healthcare Capital Partners II, L.P.   1.8%
    VHCP Co-Investment Holdings II, LLC   1.8%
    Venrock Healthcare Capital Partners III, L.P.   1.8%
    VHCP Co-Investment Holdings III, LLC   1.8%
    Venrock Healthcare Capital Partners EG, L.P.   1.8%
    VHCP Management II, LLC   1.8%
    VHCP Management III, LLC   1.8%
    VHCP Management EG, LLC   1.8%
    Nimish Shah   1.8%
    Bong Koh   1.8%

     

      (c) Number of shares as to which the person has, as of September 30, 2024:

     

      (i) Sole power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   0 
    VHCP Co-Investment Holdings II, LLC   0 
    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management II, LLC   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

     

     

     

    (ii)Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   1,204,094(1)
    VHCP Co-Investment Holdings II, LLC   1,204,094(1)
    Venrock Healthcare Capital Partners III, L.P.   1,204,094(1)
    VHCP Co-Investment Holdings III, LLC   1,204,094(1)
    Venrock Healthcare Capital Partners EG, L.P.   1,204,094(1)
    VHCP Management II, LLC   1,204,094(1)
    VHCP Management III, LLC   1,204,094(1)
    VHCP Management EG, LLC   1,204,094(1)
    Nimish Shah   1,204,094(1)
    Bong Koh   1,204,094(1)

     

      (iii) Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   0 
    VHCP Co-Investment Holdings II, LLC   0 
    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management II, LLC   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

      (iv) Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   1,204,094(1)
    VHCP Co-Investment Holdings II, LLC   1,204,094(1)
    Venrock Healthcare Capital Partners III, L.P.   1,204,094(1)
    VHCP Co-Investment Holdings III, LLC   1,204,094(1)
    Venrock Healthcare Capital Partners EG, L.P.   1,204,094(1)
    VHCP Management II, LLC   1,204,094(1)
    VHCP Management III, LLC   1,204,094(1)
    VHCP Management EG, LLC   1,204,094(1)
    Nimish Shah   1,204,094(1)
    Bong Koh   1,204,094(1)

     

    (1) Consists of (i) 316,557 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 31,668 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 855,869 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management II, LLC, VHCP Management III, LLC and VHCP Management EG, LLC.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

     

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     

     

     

     

    CUSIP No. 55234L105 Page 16 of 17

     


    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Venrock Healthcare Capital Partners EG, L.P.   VHCP Management EG, LLC
         
    By: VHCP Management EG, LLC   /s/ Sherman G. Souther
    Its: General Partner   Name: Sherman G. Souther
        Its: Authorized Signatory
    /s/ Sherman G. Souther    
    Name: Sherman G. Souther    
    Its: Authorized Signatory    

     

    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         

     

     

     

     

    CUSIP No. 55234L105 Page 17 of 17

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on April 22, 2022)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed on April 22, 2022)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on April 22, 2022)

     

     

    Get the next $LYRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LYRA

    DatePrice TargetRatingAnalyst
    5/7/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    5/7/2024$10.00 → $0.50Buy → Hold
    Jefferies
    5/7/2024Buy → Underperform
    BofA Securities
    5/6/2024Outperform → Mkt Perform
    William Blair
    10/6/2023$15.00Buy
    BTIG Research
    8/31/2023$12.00Buy
    H.C. Wainwright
    5/24/2022$15.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $LYRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

      Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

      12/3/24 8:00:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension study indicating no product-related serious adverse events and general consistency with the primary treatment phase  WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --  Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate up

      11/12/24 4:01:58 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

      -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN

      10/15/24 7:00:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    SEC Filings

    See more
    • Lyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

      6/2/25 7:22:40 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Lyra Therapeutics Inc.

      8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

      5/19/25 4:31:28 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Lyra Therapeutics Inc.

      DEFA14A - Lyra Therapeutics, Inc. (0001327273) (Filer)

      5/9/25 4:10:16 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Waksal Harlan bought $74,095 worth of shares (25,000 units at $2.96), increasing direct ownership by 11% to 261,966 units (SEC Form 4)

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      11/13/23 5:29:27 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

      SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

      12/16/24 9:02:59 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

      SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

      11/14/24 7:48:39 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

      SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

      11/14/24 5:49:14 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

      Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

      12/3/24 8:00:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lyra Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Lyra Therapeutics from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

      5/7/24 6:26:06 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Lyra Therapeutics from Buy to Hold and set a new price target of $0.50 from $10.00 previously

      5/7/24 6:25:25 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics downgraded by BofA Securities

      BofA Securities downgraded Lyra Therapeutics from Buy to Underperform

      5/7/24 6:25:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Snyderman Nancy Lynn Md

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      5/16/25 4:30:31 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Smith W Bradford

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      5/16/25 4:30:30 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Merrifield C Ann

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      5/16/25 4:30:45 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care